Pharmacodynamic Assessment of the Benztropine Analogues AHN-1055 and AHN-2005 Using Intracerebral Microdialysis to Evaluate Brain Dopamine Levels and Pharmacokinetic/pharmacodynamic Modeling

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2005 Apr 23

PMID 15846468

Citations 9

Authors

Sangeeta Raje

Jennifer Cornish

Amy H Newman

Jianjing Cao

Jonathan L Katz

Natalie D Eddington

Affiliations

Soon will be listed here.

Abstract

Purpose: The benztropine (BZT) analogues bind with high affinity to the dopamine transporter (DAT) and demonstrate a behavioral and pharmacokinetic profile unlike that of cocaine. The development of a predictive pharmacokinetic/pharmacodynamic (PK/PD) model to characterize the concentration-effect relationship between the BZT analogues and brain dopamine (DA) levels is an important step in the evaluation of these compounds as potential cocaine abuse pharmacotherapies. Hence, the objective of this study was to mathematically characterize the PD of BZT analogues and cocaine, using appropriate PK/PD models.

Methods: Dialysis probes were stereotaxically implanted into the nucleus accumbens of Sprague-Dawley rats (275-300 g). Extracellular fluid (ECF) DA levels were measured after intravenous administration of the BZT analogues AHN-1055 and AHN-2005, as well as cocaine using high performance liquid chromatography-electrochemical detection (HPLC-ECD). PD models were used to describe the relationship between the BZT analogues or cocaine and brain microdialysate DA, and suitability was based on standard goodness-of-fit criteria.

Results: The BZT analogues produced a sustained increase in brain microdialysate DA levels in comparison to cocaine. The time of maximum concentration (T(max)) for brain microdialysate DA was 2 h for AHN-1055 and 1 h for AHN-2005 compared to a T(max) of 10 min for cocaine. The duration of brain microdialysate DA elevation was approximately 12-24 h for the BZTs in comparison to 1 h for cocaine. An indirect model with inhibition of loss of response and a sigmoid E(max) model best described the PK/PD for the BZT analogues and cocaine, respectively. The 50% of maximum inhibition (IC(50)) of the loss of DA was lower for AHN-2005 (226 +/- 27.5 ng/ml) compared to AHN-1055 (321 +/- 19.7 ng/ml). In addition, the EC(50) for cocaine was 215 +/- 11.2 ng/ml.

Conclusions: The slow onset and long duration of BZT analogue-induced DA elevation may avoid the reinforcing effects and craving of cocaine. Further, the developed models will be useful in characterizing the PK/PD of other analogues and aid in the assessment of the therapeutic efficacy of the BZT analogues as substitute medications for cocaine abuse.

Citing Articles

Indirect pharmacodynamic models for responses with circadian removal.

Ayyar V, Krzyzanski W, Jusko W J Pharmacokinet Pharmacodyn. 2019; 46(1):89-101.

PMID: 30694437 PMC: 6447046. DOI: 10.1007/s10928-019-09620-z.

Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.

Tuntland T, Ethell B, Kosaka T, Blasco F, Zang R, Jain M Front Pharmacol. 2014; 5:174.

PMID: 25120485 PMC: 4112793. DOI: 10.3389/fphar.2014.00174.

Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Kohut S, Hiranita T, Hong S, Ebbs A, Tronci V, Green J Biol Psychiatry. 2014; 76(10):802-9.

PMID: 24853388 PMC: 4353924. DOI: 10.1016/j.biopsych.2014.03.031.

A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder.

Schmeichel B, Zemlan F, Berridge C Neuropharmacology. 2012; 64:321-8.

PMID: 22796428 PMC: 3445755. DOI: 10.1016/j.neuropharm.2012.07.005.

Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking.

Barak S, Carnicella S, Yowell Q, Ron D J Neurosci. 2011; 31(27):9885-94.

PMID: 21734280 PMC: 3144766. DOI: 10.1523/JNEUROSCI.1750-11.2011.

References

Newman A, Kulkarni S . Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole. Med Res Rev. 2002; 22(5):429-64. DOI: 10.1002/med.10014. View

Newman A, Kline R, Allen A, Izenwasser S, George C, Katz J . Novel 4'-substituted and 4',4"-disubstituted 3 alpha-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J Med Chem. 1995; 38(20):3933-40. DOI: 10.1021/jm00020a006. View

Kalivas P, Duffy P . Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 1990; 5(1):48-58. DOI: 10.1002/syn.890050104. View

You Z, Chen Y, Wise R . Dopamine and glutamate release in the nucleus accumbens and ventral tegmental area of rat following lateral hypothalamic self-stimulation. Neuroscience. 2001; 107(4):629-39. DOI: 10.1016/s0306-4522(01)00379-7. View

Howell L, Wilcox K . The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther. 2001; 298(1):1-6. View

Agoston G, Wu J, Izenwasser S, George C, Katz J, Kline R . Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem. 1998; 40(26):4329-39. DOI: 10.1021/jm970525a. View

Robarge M, Agoston G, Izenwasser S, Kopajtic T, George C, Katz J . Highly selective chiral N-substituted 3alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues for the dopamine transporter: synthesis and comparative molecular field analysis. J Med Chem. 2000; 43(6):1085-93. DOI: 10.1021/jm990265s. View

Katz J, Izenwasser S, Kline R, Allen A, Newman A . Novel 3alpha-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther. 1998; 288(1):302-15. View

Gorelick D . The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol. 1997; 42:995-7. DOI: 10.1016/s1054-3589(08)60914-x. View

10.

Hurd Y, Kehr J, Ungerstedt U . In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J Neurochem. 1988; 51(4):1314-6. DOI: 10.1111/j.1471-4159.1988.tb03103.x. View

11.

Newman A, Allen A, Izenwasser S, Katz J . Novel 3 alpha-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem. 1994; 37(15):2258-61. DOI: 10.1021/jm00041a002. View

12.

Tolliver B, Newman A, Katz J, Ho L, Fox L, Hsu Jr K . Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. J Pharmacol Exp Ther. 1999; 289(1):110-22. View

13.

Czoty P, Justice Jr J, Howell L . Cocaine-induced changes in extracellular dopamine determined by microdialysis in awake squirrel monkeys. Psychopharmacology (Berl). 2001; 148(3):299-306. DOI: 10.1007/s002130050054. View

14.

Rothman R . High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci. 1990; 46(20):PL17-21. DOI: 10.1016/0024-3205(90)90466-5. View

15.

Dingemanse J, Danhof M, Breimer D . Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther. 1988; 38(1):1-52. DOI: 10.1016/0163-7258(88)90101-5. View

16.

Raje S, Cao J, Newman A, Gao H, Eddington N . Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther. 2003; 307(2):801-8. DOI: 10.1124/jpet.103.053504. View

17.

Hutchaleelaha A, Sukbuntherng J, Mayersohn M . Simple apparatus for serial blood sampling in rodents permitting simultaneous measurement of locomotor activity as illustrated with cocaine. J Pharmacol Toxicol Methods. 1997; 37(1):9-14. DOI: 10.1016/s1056-8719(96)00142-6. View

18.

Jolly D, Vezina P . In vivo microdialysis in the rat: low cost and low labor construction of a small diameter, removable, concentric-style microdialysis probe system. J Neurosci Methods. 1996; 68(2):259-67. DOI: 10.1016/0165-0270(96)00089-1. View

19.

Rothman R, Mele A, REID A, Akunne H, Greig N, Thurkauf A . GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav. 1991; 40(2):387-97. DOI: 10.1016/0091-3057(91)90570-r. View

20.

Pan W, Hedaya M . An animal model for simultaneous pharmacokinetic/pharmacodynamic investigations: application to cocaine. J Pharmacol Toxicol Methods. 1998; 39(1):1-8. DOI: 10.1016/s1056-8719(97)00097-x. View